Zhitong Finance App News, Zejing Pharmaceutical (688266.SH) announced that on December 30, 2025, the company reached a strategic cooperation and licensing option agreement with AbbVie Group Holdings (registered in Bermuda) (“AbbVie”) on the global development and commercialization of ZG006 (Alveltamig). After reaching the above agreement, the company and AbbVie actively promoted the subsequent development of ZG006. The company received a down payment of 100 million US dollars from AbbVie according to the agreed schedule at the beginning of the year, and recently received a recent milestone payment of 10 million US dollars from AbbVie based on clinical trial progress.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.